Yes, anxiety is a recognized symptom of COVID-19, both during the acute infection and in the weeks or months that follow. Roughly one in three people with mild COVID-19 scores above the clinical threshold for anxiety during the illness itself, and meta-analyses place post-infection anxiety rates between 17% and 30%. This isn’t simply worry about being sick. The virus can directly affect the brain in ways that trigger or worsen anxiety, independent of any psychological stress you might feel about your diagnosis.
Anxiety During Acute COVID-19
Anxiety can appear alongside the more familiar respiratory and flu-like symptoms of a COVID-19 infection. In a study of over 2,600 patients with clinically mild cases, 32% scored at or above the clinical cutoff for generalized anxiety. A separate hospital-based analysis found anxiety was actually the most common psychiatric symptom during the acute phase, present in nearly 79% of patients who required inpatient care. That figure reflects a sicker population, but it underscores how prominent anxiety can be when the infection hits harder.
The anxiety often emerges within the first week or two of symptoms. It can feel like a sudden, unexplained sense of dread, restlessness, or an inability to calm your mind, sometimes even before respiratory symptoms become severe. People who had recent COVID symptoms in the prior 14 days showed a statistically significant increase in anxiety and depression scores compared to those without active symptoms, suggesting the infection itself is a driver rather than background pandemic stress alone.
Why COVID-19 Triggers Anxiety
The connection goes deeper than the stress of being sick. SARS-CoV-2 can invade the central nervous system, and when it does, it sets off a cascade of inflammation in the brain. Infected patients show elevated levels of inflammatory signaling molecules, particularly IL-6, IL-1β, and TNF-α. These molecules cross into brain tissue and disrupt the chemical environment that regulates mood and threat perception.
This process, called neuroinflammation, is already well established as a contributor to anxiety and depression outside of COVID. The virus essentially accelerates it. Brain imaging studies have found volume reductions in the hippocampus and amygdala, two structures central to memory and emotional regulation, that persist for years after the acute illness. These structural changes align with the long-term anxiety and memory problems many patients report.
Anxiety as a Long COVID Symptom
For many people, anxiety doesn’t resolve when the fever breaks. About 31% of people with long COVID experience clinically significant anxiety, making it one of the most common mental health symptoms alongside depression, which appears at a similar rate. The average duration of anxiety in long COVID is approximately 3.8 months, slightly longer than depression at 3.5 months.
That 3.8-month average is encouraging for most people, but it’s an average. Some recover within weeks, while others deal with anxiety that stretches well beyond six months, particularly if they had a more severe initial infection or pre-existing mental health conditions.
Who Is Most at Risk
Women are consistently more likely to develop anxiety symptoms during and after COVID-19. This pattern mirrors what’s seen in anxiety disorders broadly, but the gap appears to widen with active infection. People with pre-existing anxiety or depression are also more vulnerable to a flare-up during COVID, as the virus’s inflammatory effects can amplify an already sensitized stress response system.
Age doesn’t seem to create a clear dividing line. Hospital data show that both younger and older adults develop anxiety at similar rates during acute COVID. The severity of the initial infection matters more: those with more intense symptoms, particularly respiratory distress, report higher anxiety both during and after the illness.
Variants Make a Difference
Not all COVID-19 variants carry the same neuropsychiatric risk. A prospective study comparing Delta and Omicron infections in children found that anxiety disorder was significantly more common after Delta (12.7%) than Omicron (0.8%). Delta also produced more fatigue, weakness, and gastrointestinal changes. This aligns with the broader observation that earlier, more aggressive variants tended to cause more systemic inflammation, which in turn drove more brain-related symptoms. If you were infected during the Omicron-dominant era, your risk of post-COVID anxiety is likely lower than someone who caught Delta or the original strain.
Infection vs. Pandemic Stress
One of the trickier questions is whether the anxiety comes from the virus or from the experience of living through a pandemic. The answer, for many people, is both, but the biological component is real and measurable. The inflammatory markers found in COVID patients’ blood and cerebrospinal fluid are directly linked to anxiety through well-understood neurological pathways. People who were actually infected show higher rates of anxiety than the general population experiencing pandemic-related social stress alone. The virus doesn’t just make you worried about being sick; it changes brain chemistry in ways that produce anxiety as a physiological symptom.
Treatment and Recovery
Cognitive behavioral therapy (CBT) is considered the first-line approach for anxiety that develops after COVID-19, and it works through the same mechanisms as it does for other anxiety disorders. Internet-based and app-based CBT programs have shown promise for people still dealing with fatigue or other long COVID symptoms that make in-person appointments difficult.
Standard anti-anxiety medications, particularly SSRIs and SNRIs, are effective for post-COVID anxiety. Some of these medications may carry an additional benefit: certain SSRIs appear to have anti-inflammatory properties that could help dampen the very cytokine activity driving COVID-related anxiety in the first place. Physical exercise, mindfulness practices, and good sleep hygiene all support recovery, especially when combined with therapy.
One important caution: benzodiazepines like alprazolam and lorazepam, which are commonly prescribed for acute anxiety, can suppress breathing. For anyone still recovering from COVID-related respiratory issues, these carry extra risk and are generally avoided. Similarly, certain nerve-pain medications sometimes used for anxiety can worsen cardiac and respiratory problems in COVID patients.
Most people see meaningful improvement within a few months. The 3.8-month average duration of post-COVID anxiety suggests that for the majority, this is a temporary condition that resolves as the brain’s inflammatory response settles down, though treatment can shorten that timeline considerably.